#Investing.com - Investing.com -- Shares in Gilead Sciences Inc (NASDAQ:GILD) fell sharply in after-hours trading after sales in its popular Hepatitis C drug Harvoni tumbled 29% last quarter, dragging down company revenues overall. Over the company's second ...Shares in Gilead Sciences plunge 3% amid disappointing Harvoni sales
↧
